← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Microvascular Therapeutics, Llc
Tucson, AZ
$4,208,688
Total funding
6
Grants
Funding over time
peak $1.2M · FY2017–23$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,208,688 · 6
By mechanism
R44$1,613,934 · 1
R43$1,171,293 · 3
R33$925,231 · 1
SB1$498,230 · 1
Investigators at Microvascular Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of New Improved Perflutren Ultrasound Contrast Agent$1,229,385
R44 · FY2017 · HL
Ultrasound-mediated thrombolysis for MVO and PAO treatment.$575,012
R33 · FY2021 · HL
Selectivity and Efficacy of CD90-targeted Phase Shift Microbubbles for HIFU-mediated Non-Thermal Ablation of Brain Tumors.$397,597
R43 · FY2022 · CA
Targeted ultrasound contrast agents for the disruption of Alzheimer's plaques.$395,506
R43 · FY2020 · AG
Development of New Improved Perflutren Ultrasound Contrast Agent$384,549
R44 · FY2019 · HL
Ultrasound-Stimulated Phase-Change Contrast Agents for Sonothrombolysis.$378,190
R43 · FY2020 · HL
Ultrasound-mediated thrombolysis for MVO and PAO treatment.$350,219
R33 · FY2022 · HL
MVT-100 Manufacturing and Commercialization.$292,149
SB1 · FY2022 · HL
MVT-100 Manufacturing and Commercialization.$206,081
SB1 · FY2023 · HL